Beam stock forecast.

Nov 18, 2023 · Future criteria checks 1/6. Beam Therapeutics's earnings are forecast to decline at 11.2% per annum while its annual revenue is expected to grow at 12.2% per year. EPS is expected to decline by 3.5% per annum. Return on equity is forecast to be -82.9% in 3 years.

Beam stock forecast. Things To Know About Beam stock forecast.

Nov 25, 2023 · BEEM stock forecast for 2023 – 2027. Last updated: November 25, 2023. BEEM. Beam Global. 5.85 D 4.84% (0.27) Are you interested in Beam Global stocks prediction? If yes, then on this page you will find useful information about the dynamics of the BEEM stock price in 2022-2027. Is BEEM a good long term stock? When should I take profit in Beam ... Find the latest Roku, Inc. (ROKU) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid Term ...Track Beam Therapeutics Inc (BEAM) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAverage 51.83 75.87% Upside Low 19.00 -35.53% Downside High 95.00 222.36% Upside Broker Rating Beam Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.86 on a scale of... The current average BEAM price target, as estimated by these analysts, is $63.00. The predictions for the future BEAM stock price range from a low of $62.00 to a high of …

According to the issued ratings of 3 analysts in the last year, the consensus rating for Beam Global stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for BEEM. The average twelve-month price prediction for Beam Global is $25.00 with a high price target of $25.00 and a low price target of $25.00.Find the latest Ion Beam Applications SA (IBAB.BR) stock quote, history, news and other vital information to help you with your stock trading and investing.

January has now been and gone and turned out to be a nice gift for investors. Battered by 2022’s bear, the tech-heavy Nasdaq, in particular, put in an excellent showing, seeing out the month ~11 ...The Beam Therapeutics stock forecast for tomorrow is $ 27.79, which would represent a -6.02% loss compared to the current price. In the next week, the price of BEAM is expected to decrease by -2.93% and hit $ 28.70. As far as the long-term Beam Therapeutics stock forecast is concerned, here’s what our predictions are currently suggesting.

Find the latest HeartBeam, Inc. (BEAT) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 23, 2023 · Future criteria checks 2/6. CRISPR Therapeutics is forecast to grow earnings and revenue by 46.4% and 48.2% per annum respectively. EPS is expected to grow by 45.6% per annum. Return on equity is forecast to be 2% in 3 years. Nov 15, 2023 · Earnings vs Market: BEEM is forecast to become profitable over the next 3 years, which is considered above average market growth. High Growth Earnings: BEEM is expected to become profitable in the next 3 years. Revenue vs Market: BEEM's revenue (24.5% per year) is forecast to grow faster than the US market (7.7% per year). Beam Global has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off last year's report dates. Learn more on BEEM's earnings history.Stock Price Forecast The 12 analysts offering 12-month price forecasts for Pacific Biosciences of California Inc have a median target of 10.50, with a high estimate of 19.00 and a low estimate of ...

Get Beam Therapeutics Inc (BEAM.N) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.

Apple Inc () Stock Market info Recommendations: Buy or sell Apple stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Apple share forecasts, stock quote and buy / sell signals below.According to present data Apple's AAPL shares and potentially its market environment have been in a bullish cycle in the last 12 …

According to 4 analyst offering 12-month price targets in the last 3 months, Beam Therapeutics has an average price target of $70.25 with a high of $105.00 and a low of $37.00. Below is a summary ...Apple Inc () Stock Market info Recommendations: Buy or sell Apple stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Apple share forecasts, stock quote and buy / sell signals below.According to present data Apple's AAPL shares and potentially its market environment have been in a bullish cycle in the last 12 …Oct 15, 2020 · The Beam Therapeutics stock forecast is 57.069107374265 USD for 2024 November 25, Monday; and 177.367 USD for 2028 November 25, Saturday with technical analysis. Beam Therapeutics (BEAM) stock price prediction is 57.069107374265 USD. Drug-developer Vaxart ( VXRT -1.13%) is expected to increase its annual sales from the $4.05 million reported in 2020 to a consensus estimate of $1.047 billion by mid-decade. That's an increase of ...Find the latest HeartBeam, Inc. (BEAT) stock quote, history, news and other vital information to help you with your stock trading and investing.Following the upgrade, the consensus from 13 analysts covering Beam Therapeutics is for revenues of US$60m in 2023, implying a small 2.2% decline in sales compared to the last 12 months. Per-share ...

According to 3 analysts, the average rating for BEEM stock is "Strong Buy." The 12-month stock price forecast is $26.67, which is an increase of 343.02% from the latest price.Find the latest Ion Beam Applications SA (IBAB.BR) stock quote, history, news and other vital information to help you with your stock trading and investing.Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business.It’s difficult to put a positive spin on the current state of the stock market. While 2022’s action has seen moments of relief, for the most part, the trend has been resolutely downbeat, as reflected in the main indexes’ performances. All are down by at least double-digits; the tech-heavy NASDAQ’s 27% drop has been the most acute, while the …Weather forecasting plays a crucial role in our daily lives, helping us plan our activities and make informed decisions. But have you ever wondered how meteorologists are able to accurately predict the weather? One of the key components in ...Stock Splits: Mergers & Acquisitions: Business Services/Equipment M&A Construction M&A General Contractors & Builders M&A Consumer Goods M&A Sporting Goods & Activities M&A Office Supplies M&A Food & Beverage M&A Beverages & Wineries M&A Cigarettes & Tobacco M&A Marijuana Stocks M&A Apparel Stores M&A Department Stores M&A …Beam Therapeutics, a leading biotechnology company specializing in the development of precision genetic medicines through base editing, has recently announced Beam Therapeutics Announces Strategic Restructuring and Portfolio Prioritization for Value Creation and LongTerm Growth - Best Stocks

Find real-time ROKU - Roku Inc stock quotes, company profile, news and forecasts from CNN Business.Based on short-term price targets offered by 16 analysts, the average price target for Alibaba comes to $126.50. The forecasts range from a low of $100.00 to a high of $150.00. The average price ...

That’s the promise investors like Cathie Wood see in BEAM stock. The science is not yet at that level, though, and Beam Therapeutics lost more than a quarter of a billion dollars in 2022.$-4.18 Market Cap $2.02 B Shares Outstanding 81.50 M Public Float 68.49 M Yield BEAM is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend …January has now been and gone and turned out to be a nice gift for investors. Battered by 2022’s bear, the tech-heavy Nasdaq, in particular, put in an excellent showing, seeing out the month ~11 ...BEAM - Beam Therapeutics Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)In 2021, Vertex acquired the rights to 60% of the profits from sales of Crispr Therapeutics gene-editing therapy CTX001, now called exa-cel, for up to $1.1 billion, pending regulatory approval ...BEAM stock, the ticker symbol for Beam Therapeutics Inc, experienced a significant increase in its price on October 19, 2023. According to data from CNN Money, 14 analysts have provided 12-month price forecasts for the stock. The median target price is $61.00, with a high estimate of $105.00 and a low estimate of $27.00.The Beam Therapeutics stock forecast for tomorrow is $ 27.79, which would represent a -6.02% loss compared to the current price. In the next week, the price of BEAM is expected to decrease by -2.93% and hit $ 28.70. As far as the long-term Beam Therapeutics stock forecast is concerned, here’s what our predictions are currently suggesting. Dec 1, 2023 · John Evans. Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the ...

These 4 analysts have an average price target of $48.5 versus the current price of Beam Therapeutics at $23.8, implying upside. Below is a summary of how these 4 analysts rated Beam Therapeutics ...

The average Beam Therapeutics stock forecast 2024 represents a 80.7% increase from the last price of $28.5900001525879. For Beam Therapeutics stock forecast for 2026, 12 predictions are offered for each month of 2026 with average Beam Therapeutics stock forecast of $75.12, a high forecast of $83.03, and a low forecast of $61.46.

When builders want to create something sturdy and attractive, like a bridge that spans a large river or a tall skyscraper, they must rely on structural steel. Made up mostly of beams, structural steel comes in dozens of standard beam sizes....Find real-time BMRN - Biomarin Pharmaceutical Inc stock quotes, company profile, news and forecasts from CNN Business.Aug 13, 2023 · The Vanguard Group, Inc. is the second largest shareholder owning 8.3% of common stock, and Arch Venture Partners, L.P. holds about 7.1% of the company stock. Furthermore, CEO John Evans is the ... The Biden administration is pushing hard to promote electric vehicles (EVs). From a $7.5 billion proSee Beam Therapeutics Inc. (BEAM) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.The Beam Therapeutics stock forecast for tomorrow is $ 27.79, which would represent a -6.02% loss compared to the current price. In the next week, the price of BEAM is expected to decrease by -2.93% and hit $ 28.70. As far as the long-term Beam Therapeutics stock forecast is concerned, here’s what our predictions are currently suggesting.AADI Stock 12 Months Forecast. $33.00. (599.15% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Aadi Bioscience in the last 3 months. The average price target is $33.00 with a high forecast of $36.00 and a low forecast of $30.00. The average price target represents a 599.15% change from the last price of $4.72.Beam Therapeutics Stock Forecast Over the next 52 weeks, Beam Therapeutics has on average historically fallen by 0.2% based on the past 3 years of stock performance. Beam Therapeutics has fallen lower in 2 of those 3 years over the subsequent 52-week period, corresponding to a historical accuracy of 66.67%Meanwhile, Cathie Wood has been adding more BEAM shares to the ARKG ETF. During January, she purchased 163,838 shares. The ETF now hold 2,126,439 shares in total, currently worth ~$92.4 million ...

The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...See the latest Beam Therapeutics Inc stock price (BEAM:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Meanwhile, Cathie Wood has been adding more BEAM shares to the ARKG ETF. During January, she purchased 163,838 shares. The ETF now hold 2,126,439 shares in total, currently worth ~$92.4 million ...Beam Therapeutics (BEAM) Stock Price, News & Analysis $29.47 +1.52 (+5.44%) (As of 05:07 PM ET) Compare Today's Range $28.28 $29.84 50-Day Range $17.69 $30.76 52-Week Range $16.95 $51.60 Volume 1.35 million shs Average Volume 986,767 shs Market Capitalization $2.40 billion P/E Ratio N/A Dividend Yield N/A Price Target $48.80Instagram:https://instagram. tradestation vs ninjatraderbest algorithmic trading companieslive new york stock exchangeblue chip companys Fiscal Q3 2023 ended 9/30/23. Get the latest Beam Therapeutics Inc (BEAM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading... Oct 28, 2023 · Beam Therapeutics Inc. (BEAM) share price prediction for 2023, 2024, 2025, 2026 and 2027. BEAM one year forecast. Beam Therapeutics stock monthly and weekly forecasts. webull margin account vs cash accountbest day trading stocks 2023 Nov 25, 2023 · BEEM stock forecast for 2023 – 2027. Last updated: November 25, 2023. BEEM. Beam Global. 5.85 D 4.84% (0.27) Are you interested in Beam Global stocks prediction? If yes, then on this page you will find useful information about the dynamics of the BEEM stock price in 2022-2027. Is BEEM a good long term stock? When should I take profit in Beam ... The Beam Therapeutics stock forecast for tomorrow is $ 27.79, which would represent a -6.02% loss compared to the current price. In the next week, the price of BEAM is expected to decrease by -2.93% and hit $ 28.70. As far as the long-term Beam Therapeutics stock forecast is concerned, here’s what our predictions are currently suggesting. pros and cons of e trade John Evans. Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the ...In 2021, Vertex acquired the rights to 60% of the profits from sales of Crispr Therapeutics gene-editing therapy CTX001, now called exa-cel, for up to $1.1 billion, pending regulatory approval ...Beam Therapeutics Inc Stock Price Forecast for 2025: February 2025: Open: 7.446: Close: 0.762: Min: 0.762: Max: 8.429: Change: -877.73 % Beam Therapeutics Inc Stock Price …